Transcription of 2020 - Boehringer Ingelheim Annual Report 2019
{{id}} {{{paragraph}}}
Example: biology
2020 - Boehringer Ingelheim Annual Report 2019
B O E H R I N G E R I N G E L H E I M. A N N U A L r e p o r t . 2020. Value through innovation financial highlights summary Report Amounts in millions of EUR, unless otherwise indicated 2020 2019 Change Net sales 19,566 18,997 + 3%. by region Americas 45% 46%. Europe 30% 30%. Asia / Australia / Africa (AAA) 25% 24%. by business SUMMARY Report . 2020. Human Pharma 74% 74%. Animal Health 21% 21%. Biopharmaceutical Contract Manufacturing 4% 4%. Discontinued Operations 1% 1%. Research and development expenses 3,696 3,462 + 7%. Personnel expenses 5,587 5,367 + 4%. Average number of employees 51,944 51,015 + 2%. Operating income 4,624 3,782 + 22%. Operating income as % of net sales Group profit 3,062 2,721 + 13%. as % of net sales Group equity 17,307 14,681 + 18%. Investments in tangible assets 1,046 1,073 3%. Depreciation of tangible assets 602 585 + 3%. Top 4 products Human Pharma Top 4 products Animal Health Net Sales 2020 in million EUR Change Net sales 2020 in million EUR Change jardiance 2,480 + 15% nexgard 804 + 9%.
SUMMARY REPORT 2020 f i n a n c i a l h i g h l i g h t s s u m m a r y r e p o r t ... almost 52,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal ... the next medical breakthrough that will transform the lives of patients now, and in generations to come.
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: